跳至主要内容
临床试验/NCT00702936
NCT00702936Unknown4 期

Telmisartan vs Ramipril for Reduction of Inflammation and Recruitment of Endothelial Progenitor Cells After Acute Coronary Syndrome

Catholic University of the Sacred Heart1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2007年11月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
入组人数
50
试验地点
1
主要终点
High sensitivity C-Reactive Protein

研究概览

简要总结

The purpose of this study is to compare the antinflammatory and endothelial progenitor cell (EPC) mobilizing effect of Ramipril and Telmisartan in patients presenting with acute coronary syndrome

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
40 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Biochemical evidence of myocardial infarction as indicated by elevation of cTnT,
  • presence of ECG ischemic changes,
  • angiographic evidence of a primary coronary event, such as plaque erosion and/or rupture, fissuring, or dissection at coronary angiography,
  • successful coronary revascularization of at least one culprit coronary vessel.

排除标准

  • Age>80 years, current ACE inhibitor or ARB treatment,
  • ejection fraction <35%, infarction secondary to ischemia due to an imbalance of O2 supply and demand,
  • ECG abnormalities that could affect the recognition of ST segment shift,
  • recent or chronic infective or inflammatory diseases,
  • malignancy, and myocardial infarction,
  • surgery or trauma in the previous month.

研究组 & 干预措施

R

Active Comparator

Twenty-five patients assigned to ramipril 5 mg daily

干预措施: RAMIPRIL (Drug)

T

Active Comparator

Twenty-five patients assigned to Telmisartan 80 mg daily

干预措施: TELMISARTAN (Drug)

结局指标

主要结局

High sensitivity C-Reactive Protein

时间窗: 20 days after hospital discharge

次要结局

  • Endothelial Progenitor Cells(20 days after hospital discharge)

研究者

申办方类型
Other

研究点 (1)

Loading locations...

相似试验